ABVX
Abivax SA (ABVX) fell over 30% after-hours following the release of late-stage maintenance trial results...
Article Summary
BUY- Abivax SA (ABVX) fell over 30% after-hours following the release of late-stage maintenance trial results for Abivax ADR's oral ulcerative colitis candidate, obefazimod, showing strong and lasting benefits in 580 adults with moderate to severe colitis who had already improved during initial eight-week treatment period.
- Both the 25 mg and 50 mg doses achieved the main goal of clinical remission at week 44, with Roughly 51% of patients on either dose reaching remission compared to just 10.4% on placebo.
- The drug also succeeded on all important secondary measures including visible healing of the colon lining, deeper tissue improvement, and sustained symptom relief without the need for steroids, safety was favorable over the 44-week period with no new concerns identified, and treatment was generally well tolerated.
- While a small number of non-melanoma skin cancers were reported mainly in patients over age 60 on the higher dose, Abivax ADR said these were consistent with normal age-related risks and mostly unrelated to drug.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 13.1% | 20% | 50.0 ptsMeets Minimum (13.1%) - Target: $146.68 vs Current: $129.69 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -12.9% | 15% | 40.0 ptsMild Pullback (-12.9%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABVX
- ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
- Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
- The company was incorporated in 2013 and is headquartered in Paris, France.